MNSO (09896) Chairman of the Board and CEO Ye Guofu increased his holdings by a total of 2.1 million shares.
Miniso (09896) announces that the Board of Directors has been informed by the Company's controlling shareholder, Executive Director, and Chairman and CEO, Mr. Ye Guofu, that he purchased a total of 2.1 million shares of the company's common stock on May 29 and June 1, 2026, with his personal funds at an average price of approximately HK$25.63 per share, for a total amount of approximately HK$53.82 million (increase in shareholding).
MNSO (09896) announcement, the board of directors of the company has been informed by Mr. Ye Guofu, the controlling shareholder, executive director, chairman, and CEO of the company, that he purchased a total of 2.1 million shares of the company's common stock on the open market on May 29, 2026 and June 1, 2026 with his personal funds at an average price of approximately HK$25.63 per share, totaling approximately HK$53.82 million (increasing shareholding).
Following the increase in shareholding, Mr. Ye directly and indirectly holds a total of 792 million shares through entities under his control, representing approximately 63.9% of the company's issued shares (excluding treasury shares) as of the date of this announcement.
Mr. Ye stated that the increase in shareholding reflects his strong confidence in the overall business development prospects, growth potential, and long-term investment value of the company. Subject to compliance with applicable laws and regulatory requirements, Mr. Ye may further increase his shareholding in the company at an appropriate time.
Related Articles

Sichuan Biokin Pharmaceutical (688506.SH) plans to repurchase shares worth 100 million to 200 million yuan.

PW MEDTECH (01358) spent HK$266,800 to repurchase 228,000 shares on June 1st.

Wuxi Bio (02269) spent 49.9063 million Hong Kong dollars to repurchase 1.4485 million shares on June 1st.
Sichuan Biokin Pharmaceutical (688506.SH) plans to repurchase shares worth 100 million to 200 million yuan.

PW MEDTECH (01358) spent HK$266,800 to repurchase 228,000 shares on June 1st.

Wuxi Bio (02269) spent 49.9063 million Hong Kong dollars to repurchase 1.4485 million shares on June 1st.






